Preclinical study of a novel therapeutic vaccine for recurrent respiratory papillomatosis

Abstract Activation of antigen-specific T-lymphocyte responses may be needed to cure disorders caused by chronic infection with low-risk human papillomavirus (lrHPV). Safe and effective adjuvant therapies for such disorders are needed. The safety and efficacy of a novel gorilla adenovirus vaccine ex...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Maxwell Y. Lee, Simon Metenou, Douglas E. Brough, Helen Sabzevari, Ke Bai, Caroline Jochems, Jeffrey Schlom, Clint T. Allen
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/4ee4cb16ac8a46e2a8da230bdd87a086
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4ee4cb16ac8a46e2a8da230bdd87a086
record_format	dspace
spelling	oai:doaj.org-article:4ee4cb16ac8a46e2a8da230bdd87a0862021-12-02T17:40:46ZPreclinical study of a novel therapeutic vaccine for recurrent respiratory papillomatosis10.1038/s41541-021-00348-x2059-0105https://doaj.org/article/4ee4cb16ac8a46e2a8da230bdd87a0862021-06-01T00:00:00Zhttps://doi.org/10.1038/s41541-021-00348-xhttps://doaj.org/toc/2059-0105Abstract Activation of antigen-specific T-lymphocyte responses may be needed to cure disorders caused by chronic infection with low-risk human papillomavirus (lrHPV). Safe and effective adjuvant therapies for such disorders are needed. The safety and efficacy of a novel gorilla adenovirus vaccine expressing a protein designed to elicit immune responses directed against HPV6 and HPV11, PRGN-2012, was studied using in vitro stimulation of T lymphocytes from patients with recurrent respiratory papillomatosis, in vivo vaccination studies, and therapeutic studies in mice bearing tumors expressing lrHPV antigen. PRGN-2012 treatment induces lrHPV antigen-specific responses in patient T lymphocytes. Vaccination of wild-type mice induces E6-specific T-lymphocyte responses without toxicity. In vivo therapeutic vaccination of mice bearing established HPV6 E6 expressing tumors results in HPV6 E6-specific CD8+ T-lymphocyte immunity of sufficient magnitude to induce tumor growth delay. The clinical study of PRGN-2012 in patients with disorders caused by chronic infection with lrHPV is warranted.Maxwell Y. LeeSimon MetenouDouglas E. BroughHelen SabzevariKe BaiCaroline JochemsJeffrey SchlomClint T. AllenNature PortfolioarticleImmunologic diseases. AllergyRC581-607Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Vaccines, Vol 6, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Maxwell Y. Lee Simon Metenou Douglas E. Brough Helen Sabzevari Ke Bai Caroline Jochems Jeffrey Schlom Clint T. Allen Preclinical study of a novel therapeutic vaccine for recurrent respiratory papillomatosis
description	Abstract Activation of antigen-specific T-lymphocyte responses may be needed to cure disorders caused by chronic infection with low-risk human papillomavirus (lrHPV). Safe and effective adjuvant therapies for such disorders are needed. The safety and efficacy of a novel gorilla adenovirus vaccine expressing a protein designed to elicit immune responses directed against HPV6 and HPV11, PRGN-2012, was studied using in vitro stimulation of T lymphocytes from patients with recurrent respiratory papillomatosis, in vivo vaccination studies, and therapeutic studies in mice bearing tumors expressing lrHPV antigen. PRGN-2012 treatment induces lrHPV antigen-specific responses in patient T lymphocytes. Vaccination of wild-type mice induces E6-specific T-lymphocyte responses without toxicity. In vivo therapeutic vaccination of mice bearing established HPV6 E6 expressing tumors results in HPV6 E6-specific CD8+ T-lymphocyte immunity of sufficient magnitude to induce tumor growth delay. The clinical study of PRGN-2012 in patients with disorders caused by chronic infection with lrHPV is warranted.
format	article
author	Maxwell Y. Lee Simon Metenou Douglas E. Brough Helen Sabzevari Ke Bai Caroline Jochems Jeffrey Schlom Clint T. Allen
author_facet	Maxwell Y. Lee Simon Metenou Douglas E. Brough Helen Sabzevari Ke Bai Caroline Jochems Jeffrey Schlom Clint T. Allen
author_sort	Maxwell Y. Lee
title	Preclinical study of a novel therapeutic vaccine for recurrent respiratory papillomatosis
title_short	Preclinical study of a novel therapeutic vaccine for recurrent respiratory papillomatosis
title_full	Preclinical study of a novel therapeutic vaccine for recurrent respiratory papillomatosis
title_fullStr	Preclinical study of a novel therapeutic vaccine for recurrent respiratory papillomatosis
title_full_unstemmed	Preclinical study of a novel therapeutic vaccine for recurrent respiratory papillomatosis
title_sort	preclinical study of a novel therapeutic vaccine for recurrent respiratory papillomatosis
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/4ee4cb16ac8a46e2a8da230bdd87a086
work_keys_str_mv	AT maxwellylee preclinicalstudyofanoveltherapeuticvaccineforrecurrentrespiratorypapillomatosis AT simonmetenou preclinicalstudyofanoveltherapeuticvaccineforrecurrentrespiratorypapillomatosis AT douglasebrough preclinicalstudyofanoveltherapeuticvaccineforrecurrentrespiratorypapillomatosis AT helensabzevari preclinicalstudyofanoveltherapeuticvaccineforrecurrentrespiratorypapillomatosis AT kebai preclinicalstudyofanoveltherapeuticvaccineforrecurrentrespiratorypapillomatosis AT carolinejochems preclinicalstudyofanoveltherapeuticvaccineforrecurrentrespiratorypapillomatosis AT jeffreyschlom preclinicalstudyofanoveltherapeuticvaccineforrecurrentrespiratorypapillomatosis AT clinttallen preclinicalstudyofanoveltherapeuticvaccineforrecurrentrespiratorypapillomatosis
_version_	1718379760497721344

Preclinical study of a novel therapeutic vaccine for recurrent respiratory papillomatosis

Ejemplares similares